Dogwood Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Five proposals, including stock conversions and an equity plan, were presented and approved by majority vote. No questions were raised, and all voting procedures complied with legal and NASDAQ requirements. Final results will be filed with the SEC.
-
Halneuron’s phase II-B trial for chemotherapy-induced neuropathy pain is progressing well, with an interim analysis set for Q4 and final data expected mid-2026. SP16, a novel LRP1 agonist, enters a fully NCI-funded phase I-B trial next year, offering complementary mechanisms and market expansion opportunities.
-
The company is advancing Halneuron, a selective Nav1.7 inhibitor, through a phase II-B trial for chemotherapy-induced neuropathic pain, with interim results expected by year-end and final data in mid-2026. A synthetic formulation aims to reset the patent clock, and the company maintains a strong financial position with support from major shareholders.
-
Halneuron, a non-opioid pain therapy, shows strong efficacy and safety in cancer-related pain, with long-lasting relief and no addiction risk. Key milestones include new IP filings, interim phase II-B data in Q4 2025, and final results in mid-2026.
Fiscal Year 2024
-
Dogwood Therapeutics completed a transformative merger and secured $19.5M in financing, expanding its pipeline to include Halneuron and antiviral programs. Key clinical milestones are expected in 2024-2025, targeting large unmet needs in pain and Long COVID.
-
A merger formed Dogwood Therapeutics, combining late-stage assets for pain and fatigue disorders and securing $24M in funding. Halneuron’s U.S. Phase IIb trial for neuropathic pain starts in Q1 2025, while key long COVID data for IMC-2 is expected in Q4.
-
A newly formed biotech integrates two companies, expands its pipeline with a first-in-class non-opioid pain therapy and combination antivirals, and secures $19.5M in strategic financing. The merger targets large unmet needs in pain and long COVID, with key data readouts expected within a year.